Pramodini Medicare Limited, incorporated in September 2000 (originally as Pramodini Medicare Private Limited) in Andhra Pradesh, operates in the diagnostics sector with a focus on technology-enabled healthcare testing and imaging. It converted to a public limited company and was renamed Pramodini Medicare Limited in November 2025.
The company provides diagnostic services across radiology, clinical laboratory, and nuclear medicine to public hospitals, private hospitals, select Government of India PSUs, and medical colleges in tier I, tier II, and tier III cities across India. Its radiology offerings include MRI, CT scan, X-ray, ultrasound with colour doppler, mammography, DEXA scan, and interventional radiology. Clinical laboratory services cover haematology, microbiology, immunology, pathology, and biochemistry, while nuclear medicine includes PET-CT, SPECT, and nuclear therapy.
Operations also include 24x7 teleradiology services from its registered office in Vijayawada. The company’s testing supports routine and specialized needs across patient diagnosis, disease prevention, and monitoring, including prediction, early detection, screening, confirmation, and ongoing disease management.
Pramodini Medicare runs its business through multiple engagement models: Public Private Partnerships with government hospitals and government teaching hospitals, Private Private Partnerships with private hospitals, strategic partnerships with Government of India PSUs, and standalone private centres. The company has filed a Draft Prospectus with SEBI for an IPO of 58,51,200 equity shares (face value Rs 10), comprising a fresh issue of 53,50,000 shares and an offer for sale of 5,00,400 shares.
